Recent Posts
- And that’s a wrap 2023! Christmas with IR Department
- This is what the ASX and investors expect for gender diversity on your board
- 5 key lessons any company can take away from our foundational ESG report
- What small caps can take away from Amazon’s move to write emissions data into its supplier standards
- How Australian small caps are likely to be impacted by the new ISSB sustainability disclosure standards
Archives
HaemaLogiX's Tertia Dex explains the KappaMab antibody
HaemaLogix's Chief Manufacturing and Development Officer, Tertia Dex, explains the fascinating process to manufacture KappaMab, a highly-targeted antibody designed to treat mutliple myeloma.